MPLT news

Latest 1 stories · newest Nov 16, 2026

MPLT
MapLight Reports Q3 2026 Financials and Outlines Plans for Confirmatory Phase 3 Trial

MapLight Therapeutics ended the quarter with $463.4 million in cash and announced initiation of ZEPHYR-2, a Phase 3 schizophrenia trial topline results of which are expected in late 2027, alongside ongoing enrollment for ADP studies.

BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.

The same MPLT feed as JSON for your bot or app:

GET https://api.brieftape.com/v1/tickers/MPLT/newsSTART FREE